Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.53 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | PLK1 | P53350 | 4/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826566 | 0.92 | AURKA (0.70) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL13191062 | 0.92 | AURKA (0.60) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL12826702 | 0.91 | LRRK2 (0.62) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL12826695 | 0.89 | LRRK2 (0.67) | AURKAAURKBPTK2LRRK2 | |
| SCHEMBL12826418 | 0.89 | LRRK2 (0.67) | AURKAAURKBPTK2LRRK2 | |
| SCHEMBL12826572 | 0.88 | LRRK2 (0.59) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL12826568 | 0.87 | AURKA (0.59) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL12826856 | 0.87 | AURKA (0.56) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL16995449 | 0.87 | PTK2 (0.57) | AURKAAURKBPTK2LRRK2BRD4 | |
| SCHEMBL12826947 | 0.87 | LRRK2 (0.56) | AURKAAURKBLRRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408752-B1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-08-12 | — | — | EP | disclosed |
| US-20140051674-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-20 | — | — | US | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051674-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | AURKA 2693/4885AURKB 1255/4885PTK2 1621/4885 |
| US-20110071158-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | AURKA 2693/4885AURKB 1255/4885PTK2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.